Bill & Melinda Gates Foundation

ALL LIVES HAVE EQUAL VALUE
Our work in China

Guided by the belief that all lives have equal value, the Bill & Melinda Gates Foundation fights poverty, disease, and inequity around the world. We fund new ideas and encourage innovative partnerships so that philanthropic, public, and private resources will do the greatest good for the most people. Our vision is a world where every person has the opportunity to live a healthy, productive life.

Ever since we opened our Beijing office in 2007, we have been committed to supporting our Chinese partners as they play an ever-increasing role in improving the health and well-being of people both in China and around the world. Today, China is a key strategic partner on our global health and development goals. We provide financial and technical support to our Chinese partners and build bridges for international cooperation to help them accelerate innovations in health, agricultural development and poverty reduction. We create broad partnerships to ensure these innovations reach vulnerable populations at scale as quickly as possible. Together we have seen the tremendous impact that life-saving innovations can have when they become available to those most in need.

Students at Hua Ao School. The school mainly serves children from low-income migrant families. Beijing, China.
Advancing global health innovation, equity and accessibility

Every year, millions of people die of preventable diseases because they lack access to vaccines, treatments, and diagnostic tools, and most of them live in low- and middle-income countries. By focusing on each aspect of the global health innovation value chain, from research and development to translational science and commercialization to regulatory approval and delivery, we aim to unlock China’s potential, drive systemic change, and contribute to improved global health outcomes.

Strengthening the global health product innovation ecosystem: By pooling resources and expertise from the public and private sectors, we help foster an innovation ecosystem that enables critical international collaboration from scientific discovery to research and development, production, and delivery. We also facilitate access to high-quality, affordable vaccines, treatments and other medical and health products from China for those most in need worldwide, to strengthen the world’s capability to respond to major public health challenges.

Supporting China’s effort to improve its medical products regulatory system up to international standards: We provide support to China’s regulatory bodies to help boost their overall regulatory capacity and improve drug review and approval systems. We also facilitate exchanges and collaborations between Chinese regulatory bodies and international organizations to align China’s practices and processes with international norms.

Accelerating global efforts to eradicate malaria: We support the adaptation of China’s proven prevention and control models in regions with high malaria burdens, especially in Africa. We also help accelerate the introduction of high-quality, low-cost, Chinese-made anti-malarial products to the global market, work with the Chinese Center for Disease Control and Prevention to help African countries improve their disease surveillance networks and capabilities, and invest in the innovation and scale-up of anti-malarial tools to continuously provide new interventions in support of the global malaria eradication goal.

Strengthening China’s National Immunization Program (NIP): We work with Chinese Center for Disease Control and Prevention, the Technical Working Groups of the National Immunization Advisory Committee, and other partners to improve China’s vaccine industry ecosystem in multiple areas, including immunization strategy, vaccine supply, delivery services, and financing and payment methods. Our goal is to introduce new vaccines such as human papillomavirus (HPV) vaccine, pneumococcal conjugate vaccine (PCV), rotavirus vaccine and Haemophilus influenzae type b (Hib) vaccine into China’s NIP to protect more children and other vulnerable populations.

Reducing the disease burden of tuberculosis (TB): Since 2009, we have partnered with China’s National Health Commission on a joint TB prevention and control program, launching pilot projects to explore new models for TB and multidrug-resistant TB prevention and control, as well as improving treatment regime and compliance. We also work with multiple government agencies to implement innovative financing and payment methods that relieve the high costs of treatment and advocate for increased investment in the research and development of diagnostic tools, drugs, and vaccines.

Preventing and controlling HIV/AIDS: We have worked with China’s National Health Commission to expand coverage of new testing services and to advocate for the role social organizations can play in curbing the spread of HIV/AIDS. We have also supported programs and campaigns to raise awareness of HIV/AIDS prevention and treatment, fight stigma, and reduce mother-to-child HIV transmission. These efforts have helped China further slow the spread of the disease.

Accelerating the innovation and commercialization of sanitation technologies: We collaborate with public and private sector partners to develop and commercialize safe, affordable sanitation and waste treatment technologies, explore innovative service delivery models, and cultivate markets to improve sanitation conditions for the world’s most vulnerable people. This helps prevent deaths from diseases such as diarrhea, typhoid, and cholera and reduces environmental pollution.

Improving health for all: In accordance with the Healthy China 2030 blueprint, we draw on our own experience and expertise to help China’s health authorities conduct multiple programs to improve people’s health and address health inequities. These programs aim to improve primary healthcare in rural areas, advocate breastfeeding and improve child nutrition, and reduce the financial burdens and health risks associated with tobacco use.

Scientists working at the Global Health Drug Discovery Institute (GHD3i), Beijing, China.
Driving agricultural development to alleviate poverty in African countries

Three-quarters of the world’s poorest people are smallholder farmers, and most of them live in sub-Saharan Africa and South Asia. Agricultural development has proven to be a path out of poverty. We work with Chinese partners to help African countries establish modern seed systems that integrate rice seed breeding, production, and extension. We also help smallholder farmers in Africa increase productivity and boost income through participation in the global food value chain, which ultimately contributes to improving food security and ending extreme poverty.

Facilitating innovation and exchanges in development cooperation

If the international development community is to help more people lift themselves out of extreme poverty, development aid and cooperation must be more effective. We leverage our global partnership network to support China in increasing the effectiveness of its bilateral aid efforts, while expanding collaboration with multilateral financing institutions and new multilateral partnerships. We have also been working with Chinese and global partners to promote international exchanges on the issue of poverty reduction and to share China’s successful experience in alleviating poverty with other developing nations.

Promoting philanthropic development and collaboration

We believe that philanthropy can fill the space between the public and private sectors and draw on the strengths of partners in both areas to seek innovative and effective solutions to social issues and inequities. To advance philanthropic development, we work closely with all sectors of society in China to build the country’s philanthropic ecosystem, support research and advocacy, promote innovation, and encourage more charitable giving.
We work with partners around the globe to save and improve people’s lives

01 Seattle, United States
02 Washington, D.C., United States
03 London, United Kingdom
04 Berlin, Germany
05 Abuja, Nigeria
06 Johannesburg, South Africa
07 Addis Ababa, Ethiopia
08 Delhi, India
09 Beijing, China

US$65.6 billion
Total grant payments since inception

US$6.7 billion
Total 2021 charitable support

US$53.3 billion
Foundation Trust endowment

144 Countries
1736 Employees
1381 Grantees

For the year ended December 31, 2021.